Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Autor: Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., Kastelein, J. J., ODYSSEY LONG TERM Investigators, Lembo, Giuseppe

Publikováno v: Robinson, J G, Farnier, M, Krempf, M, Bergeron, J, Luc, G, Averna, M, Stroes, E S, Langslet, G, Raal, F J, El Shahawy, M, Koren, M J, Lepor, N E, Lorenzato, C, Pordy, R, Chaudhari, U, Kastelein, J J P, ODYSSEY LONG TERM Investigators & Torp-Pedersen, C 2015, ' Efficacy and safety of alirocumab in reducing lipids and cardiovascular events ', The New England Journal of Medicine, vol. 372, no. 16, pp. 1489-1499 . https://doi.org/10.1056/NEJMoa1501031
New England journal of medicine, 372(16), 1489-1499. Massachussetts Medical Society
New England Journal of Medicine
New England Journal of Medicine, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩
New England Journal of Medicine, Massachusetts Medical Society, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and long

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48df7487c03f82bdbce1a49c5d5d435f
https://doi.org/10.1056/nejmoa1501031

High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review.

Autor: Chen, Qiaofei^1,2,3 (AUTHOR) chenqf56@mail2.sysu.edu.cn, Abudukeremu, Ayiguli^1,2,3 (AUTHOR) ayglabdkrm@163.com, Li, Kaiwen⁴ (AUTHOR) likw9@mail2.sysu.edu.cn, Zheng, Minglong¹ (AUTHOR) zhengmlong3@mail2.sysu.edu.cn, Li, Hongwei¹ (AUTHOR) lihw57@mail2.sysu.edu.cn, Huang, Tongsheng¹ (AUTHOR) huangtsh3@mail2.sysu.edu.cn, Huang, Canxia¹ (AUTHOR) huangcx5@mail.sysu.edu.cn, Wen, Kexin¹ (AUTHOR) wenkx@mail2.sysu.edu.cn, Wang, Yue¹ (AUTHOR) wangy2323@mail2.sysu.edu.cn, Zhang, Yuling^1,2,3,5 (AUTHOR) zhyul@mail.sysu.edu.cn

Publikováno v: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7856. 19p.

中国缺血性卒中及短暂性脑缺血发作患者 血脂长期管理科学声明.

Autor: 王拥军¹ yongjunwang@ncrcnd.org.cn

Publikováno v: Chinese Journal of Stroke. Apr2024, Vol. 19 Issue 4, p440-451. 12p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence.

Autor: Zhu XB; Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Xu YY; Department of Pharmacy, Pingyang Hospital Affiliated to Wenzhou Medical University (The People's Hospital of Pingyang), Wenzhou, China., Li LC; Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Sun JB; Department of Pharmacy, Deqing People's Hospital, Huzhou, China., Wang YZ; Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Chen J; Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Wang C; Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Zhang S; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China., Jin LY; Department of Pharmacy, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Publikováno v: Drug development research [Drug Dev Res] 2024 Feb; Vol. 85 (1), pp. e22131. Date of Electronic Publication: 2023 Nov 09.